Here are the 424B prospectus supplements from AgomAb Therapeutics NV (AGMB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AGMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGMB filings page.
AgomAb Therapeutics is conducting an initial public offering of $200,000,000 by offering 12,500,000 ADSs at $16.00 per ADS, with an underwriter option for up to 1,875,000 ADSs; ADSs will trade on Nasdaq under the symbol AGMB.
The prospectus states estimated net proceeds of approximately $181 million to advance clinical development of ontunisertib and AGMB-447, fund preclinical programs, a milestone payment related to the Origo acquisition, and general corporate purposes. The company is an emerging growth company and a foreign private issuer, reports under IFRS, and expects delivery of ADSs on February 9, 2026.